论文部分内容阅读
目的:观察凯西莱联合胸腺肽治疗慢性乙型肝炎的疗效。方法:将我院收治的83例慢性乙型肝炎患者随机分为治疗组43例和对照组40例。两组均不用其他褪黄、降酶及抗病毒药物。在基础治疗相同的基础上,治疗组给予静脉滴注凯西莱200 mg/d+胸腺肽20 mg/d;对照组则给予静脉滴注还原型谷胱甘肽1 200 mg/d,两组疗程均为4周。观察治疗前后血清转氨酶(ALT、AST)、白蛋白(Alb)、球蛋白(Glb)、胆红素(TBil、DBil)变化。结果:两组肝功能、临床症状均明显改善,两组ALT、AST、Alb、Glb、TBil较治疗前均下降,差异有非常显著性(P<0.01),但组间比较差异无显著性(P>0.05)。两组总有效率分别为95.35%和85%,差异有显著性(P<0.01)。结论:凯西莱注射液联合胸腺肽治疗慢性乙型肝炎不但疗效确切,而且安全可靠。
Objective: To observe the cuixilei thymosin combined treatment of chronic hepatitis B curative effect. Methods: 83 cases of chronic hepatitis B admitted to our hospital were randomly divided into treatment group (43 cases) and control group (40 cases). No other two groups of yellowing, reducing enzyme and antiviral drugs. On the basis of the same basic treatment, the treatment group given intravenous ketosi 200 mg / d + thymosin 20 mg / d; control group was given intravenous drip reduction of glutathione 1 200 mg / d, two groups of treatment are For 4 weeks. The changes of serum aminotransferase (ALT, AST, Alb, Glb, TBil, DBil) before and after treatment were observed. Results: The liver function and clinical symptoms of both groups were significantly improved. The levels of ALT, AST, Alb, Glb and TBil in both groups were significantly lower than those before treatment (P <0.01), but there was no significant difference between the two groups P> 0.05). The total effective rate was 95.35% and 85% in both groups, with significant difference (P <0.01). Conclusion: Kesilai injection combined with thymosin in the treatment of chronic hepatitis B is not only effective, but also safe and reliable.